Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials

2016 ◽  
Vol 54 (2) ◽  
pp. 635-643 ◽  
Author(s):  
Shinji Matsunaga ◽  
Taro Kishi ◽  
Nakao Iwata
Keyword(s):  
Randomized Controlled Trials ◽  
Psychological Symptoms ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Behavioral And Psychological Symptoms

scholarly journals Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials

2017 ◽  
Vol 30 (3) ◽  
pp. 285-293 ◽  
Author(s):  
Egemen Savaskan ◽  
Heiko Mueller ◽  
Robert Hoerr ◽  
Armin von Gunten ◽  
Serge Gauthier
Keyword(s):  
Randomized Controlled Trials ◽  
Ginkgo Biloba ◽  
Fixed Effects ◽  
Psychological Symptoms ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Caregiver Distress ◽  
Egb 761 ◽  
Randomized Controlled ◽  
Behavioral And Psychological Symptoms

ABSTRACTBackground:In randomized controlled trials, Ginkgo biloba extract EGb 761® has been found to be effective in the treatment of behavioral and psychological symptoms of dementia (BPSD).Methods:To assess the effects of EGb 761® on specific BPSD, we analyzed data from all randomized, placebo-controlled, at least 20-week, trials of EGb 761® enrolling patients with dementia (probable Alzheimer's disease (AD), probable vascular dementia or probable AD with cerebrovascular disease) who had clinically significant BPSD (Neuropsychiatric Inventory (NPI) total score at least 6). Data were pooled and joint analyses of NPI single item composite and caregiver distress scores were performed by meta-analysis with a fixed effects model.Results:Four trials involving 1628 patients (EGb 761®, 814; placebo, 814) were identified; treatment duration was 22 or 24 weeks; the daily dose of EGb 761® was 240 mg in all trials. Pooled analyses including data from the full analysis sets of all trials (EGb 761®, 796 patients; placebo, 802 patients) revealed significant superiority of EGb 761® over placebo in total scores and 10 single symptom scores. Regarding caregiver distress scores, EGb 761®-treated patients improved significantly more than those receiving placebo in all symptoms except delusions, hallucinations, and elation/euphoria. The benefit of EGb 761® mainly consists of improvement in symptoms present at baseline, but the incidence of some symptoms was also decreased.Conclusions:Twenty two- to twenty four-week treatment with Ginkgo biloba extract EGb 761® improved BPSD (except psychotic-like features) and caregiver distress caused by such symptoms.

Interventions for suicide and self-injury: A meta-analysis of randomized controlled trials across nearly 50 years of research.

2020 ◽  
Vol 146 (12) ◽  
pp. 1117-1145
Author(s):  
Kathryn R. Fox ◽  
Xieyining Huang ◽  
Eleonora M. Guzmán ◽  
Kensie M. Funsch ◽  
Christine B. Cha ◽  
...  
Keyword(s):  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Self Injury
Sign in / Sign up

Export Citation Format

Share Document